NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Corona Remedies Recommends ₹10 Dividend and Appoints Walker Chandiok as New Auditor
Corona Remedies has announced a final dividend of ₹10 per share (100% of face value) for FY 2025-26, with the record date set for June 19, 2026. The company reported unmodified audit reports for its standalone and consolidated financial results for the fiscal year ended March 31, 2026. A significant governance update includes the proposed appointment of Walker Chandiok & Co LLP as the new statutory auditor for a five-year term. Additionally, the board has approved the re-appointment of Dr. Kirtikumar Mehta as Chairman for another five-year term starting April 2027.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26Fixed June 19, 2026, as the record date for dividend entitlement with payment by August 07, 2026Proposed appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for a 5-year tenureConfirmed unmodified audit reports for both Standalone and Consolidated FY26 financial resultsRe-appointed Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for a 5-year term
👀 கவனிக்க வேண்டியவை
Investors should track the record date of June 19 to be eligible for the ₹10 dividend and may view the transition to a major audit firm as a positive step for corporate governance.
CORONA Remedies Acquires Wokadine® from Dr. Reddy’s; Enters INR 648 Cr Market
CORONA Remedies has announced the strategic acquisition of the Wokadine® brand from Dr. Reddy’s Laboratories, marking its fifth acquisition to date. Wokadine® is currently ranked #2 in the Indian Povidone Iodine market, which is valued at approximately INR 648 crore. The transaction, which includes 14 SKUs, will be entirely funded through internal accruals and cash reserves, ensuring no additional debt burden. This acquisition allows CORONA to leverage its existing distribution network and expand its presence among surgeons, ENT specialists, and gynecologists.
முக்கிய அம்சங்கள்
Acquisition of Wokadine®, the #2 ranked brand in India's Povidone Iodine marketEntry into the INR 648 crore Povidone Iodine therapeutic segment with 14 SKUsTransaction is fully funded through internal accruals and cash, maintaining a healthy balance sheetStrategic synergy with existing focus areas including Surgeons, ENT, and GynaecologistsMarks the 5th acquisition for CORONA Remedies, demonstrating a consistent inorganic growth strategy
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth move that strengthens the company's portfolio without leveraging the balance sheet. Monitor the integration and subsequent revenue growth from the Wokadine® brand in upcoming quarterly results.
CORONA Remedies Q3 FY'26 Revenue Up 15% to ₹342 Cr; PAT Grows 24%
CORONA Remedies reported a strong Q3 FY'26 with revenue growing 15% YoY to ₹342 crores and adjusted PAT rising 24% to ₹56 crores. The company significantly outperformed the Indian Pharmaceutical Market (IPM) with an 18.9% growth rate, securing the 28th rank among top pharma firms. EBITDA margins improved by 100 bps to 24.3%, supported by a high contribution from the chronic and semi-chronic segments which now account for over 70% of revenue. Management maintained a positive outlook, citing upcoming commercialization of acquired Bayer brands and new EAEU GMP accreditation for international expansion.
முக்கிய அம்சங்கள்
Q3 FY'26 revenue increased 15% YoY to ₹342 crores, while 9M FY'26 revenue reached ₹1,050 crores.EBITDA margins expanded by 100 bps to 24.3% in Q3, with 9M PAT growing 31% YoY to ₹154 crores.Outperformed IPM growth of 9.6% by recording 18.9% growth, moving up to the 28th rank in the market.Received EAEU GMP accreditation, opening access to a $25 billion pharmaceutical market across five member countries.Commercialization of the Bayer brand portfolio is set to begin in Q4 FY'26 with the launch of Noklot Plus.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong growth play given the company's consistent outperformance of the broader market and healthy return ratios like an ROE of 31%. The integration of Bayer brands and international expansion into EAEU markets provide clear catalysts for sustained earnings growth.
CORONA Remedies Q3 FY26: Adjusted PAT Up 23.7% to ₹55.6 Cr; EBITDA Margins Expand to 24.3%
CORONA Remedies reported a strong Q3 FY26 performance with revenue growing 15% YoY to ₹342.4 crore and adjusted PAT rising 23.7% to ₹55.6 crore. The company demonstrated significant operational efficiency, with EBITDA margins expanding by 100 bps to 24.3% and 9M FY26 ROCE standing at a robust 48.0%. A key growth catalyst is the recent EAEU-GMP certification for its Bhayla facility, which opens access to a USD 25 billion market across five Eurasian countries including Russia. The business remains heavily skewed towards high-margin chronic therapies, which now contribute 71.6% of total revenue.
முக்கிய அம்சங்கள்
Revenue for 9M FY26 crossed the ₹1,000 Cr milestone, reaching ₹1,050.1 Cr, up 16.3% YoY.Adjusted PAT for 9M FY26 grew by 30.7% YoY to ₹154.1 Cr, reflecting strong bottom-line momentum.Chronic therapy segment continues to lead, contributing 71.6% of total revenue in Q3 and 9M FY26.Bhayla facility received EAEU-GMP certification in January 2026, enabling entry into five key Eurasian markets.Maintained superior return ratios with 9M FY26 ROE at 31.1% and ROCE at 48.0% (annualized).
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's consistent margin expansion and its successful transition into a chronic-heavy portfolio. The recent EAEU-GMP certification provides a significant international growth runway that could re-rate the stock as export revenues scale.
CORONA Remedies Reaffirms CARE A+; Stable Credit Rating for ₹95 Crore Bank Facilities
CARE Ratings has reaffirmed the credit ratings for CORONA Remedies Limited's bank facilities totaling ₹95 crore. The long-term facilities, which were reduced from ₹73 crore to ₹25 crore, maintained a 'CARE A+; Stable' rating. Additionally, the combined long-term and short-term facilities of ₹70 crore were reaffirmed at 'CARE A+; Stable / CARE A1'. This reaffirmation reflects the company's consistent operational and financial performance through FY25 and the first half of FY26.
முக்கிய அம்சங்கள்
CARE Ratings reaffirmed 'CARE A+; Stable' for ₹25 crore long-term bank facilities.Long-term bank facilities were significantly reduced from ₹73 crore to ₹25 crore, indicating debt reduction.Reaffirmed 'CARE A+; Stable / CARE A1' for ₹70 crore long-term/short-term bank facilities.The rating review was based on audited FY25 and unaudited H1FY26 financial performance.Total rated bank facilities currently stand at ₹95 crore across ICICI Bank and Citi Bank.
👀 கவனிக்க வேண்டியவை
The reaffirmation of a high credit rating and the reduction in long-term debt facilities are positive indicators of financial health. Investors should maintain their positions as the company demonstrates stable creditworthiness and disciplined debt management.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Corona Remedies Q3FY26 PAT jumps 23.7% YoY to ₹55.56 Cr; Revenue up 15%
CORONA Remedies reported a strong Q3FY26 with revenue growing 15% YoY to ₹342.42 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth. Adjusted Profit After Tax (PAT) saw a significant rise of 23.7% YoY to ₹55.56 Cr, while 9-month PAT grew by 30.7%. The company maintained robust operational efficiency with an EBITDA margin of 24.3% for the quarter and an impressive annualized RoCE of 48.0%. Management remains optimistic about maintaining a trajectory of 15% revenue and 20% PAT growth going forward.
முக்கிய அம்சங்கள்
Q3FY26 Revenue grew 15.0% YoY to ₹342.42 Cr; 9M Revenue reached ₹1,050.09 Cr.Adjusted PAT for Q3 rose 23.7% YoY to ₹55.56 Cr, excluding one-time labour code impacts of ₹14.29 Cr.Strong profitability metrics with Q3 EBITDA margin at 24.3% and 9M annualized RoCE at 48.0%.Efficient working capital management with Net Working Capital days standing at just 18 days.9M OCF to EBITDA ratio remains healthy at 86.3%, indicating strong cash flow generation.
👀 கவனிக்க வேண்டியவை
Investors should view this performance positively as the company is consistently outperforming the market and delivering high return ratios. The stock warrants a positive outlook given the management's confidence in maintaining a 15-20% growth trajectory and efficient capital utilization.
CORONA Remedies has received the EAEU-GMP certification for its Bhayla, Gujarat facility, enabling entry into five Eurasian nations including Russia and Belarus. This certification provides strategic access to a pharmaceutical market estimated at USD 25 billion through a B2B business model. The expansion focuses on the company's core therapeutic pillars: Women’s Health, Cardio-Diabetes, Pain Management, and Urology. As the fastest-growing company among the top 30 in the Indian Pharmaceutical Market, this move significantly strengthens its international footprint.
முக்கிய அம்சங்கள்
Received EAEU-GMP certification for the finished dosage facility situated at Bhayla, GujaratGains access to a pharmaceutical market estimated at USD 25 billion across five member nationsEntry into Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan under a B2B business modelIdentified as the fastest growing company among the top 30 in the Indian Pharmaceutical Market as of September 2025Strengthens global presence in key therapeutic areas including Women’s Health and Cardio-Diabetes
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to convert this certification into revenue-generating B2B partnerships in the Eurasian region. This development is a positive indicator of the company's quality standards and long-term export growth potential.
CORONA Remedies Receives EAEU GMP Certification for Bhayla Facility
CORONA Remedies Limited has successfully obtained the Good Manufacturing Practice (GMP) Certificate of Compliance from the Eurasian Economic Union (EAEU). This certification applies to the company's finished dosage manufacturing facility located in Bhayla, Gujarat. The approval covers a significant economic bloc consisting of five countries: Russia, Kazakhstan, Kyrgyzstan, Belarus, and Armenia. This regulatory milestone is a critical step for the company to begin exporting and marketing its products within these international territories.
முக்கிய அம்சங்கள்
Received GMP Certificate of Compliance from the Eurasian Economic Union (EAEU)Certification applies to the finished dosage facility situated at Bhayla, GujaratEnables market access to 5 countries: Russia, Kazakhstan, Kyrgyzstan, Belarus, and ArmeniaStrategic approval paves the way for international expansion and export revenue growth
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's progress in securing product-specific registrations in these new markets to gauge the timeline for revenue contribution. This development strengthens the company's long-term export potential and geographic diversification.
CORONA Remedies Targets 15% Revenue and 20% PAT CAGR in Maiden Earnings Call
CORONA Remedies, which listed in December 2025, is positioning itself as a high-growth domestic pharma player with 70% revenue from chronic and semi-chronic segments. The company is currently the fastest-growing among India's top 30 pharma firms, outpacing the market by 1.5x. Management has provided a robust outlook, targeting 15% revenue and 20% PAT growth over the next 3-4 years. Growth will be supported by a new 400 million unit capacity in Gujarat and the integration of seven brands acquired from Bayer Zydus.
முக்கிய அம்சங்கள்
Management targets 15% revenue CAGR and 20% PAT growth over the next 3-4 years.Acquired 7 brands from Bayer Zydus in July 2025, entering the INR 1,500+ crore anti-platelet market.Commissioned new capacity of 400 million tablets/capsules at Gujarat facility in December 2025.Chronic and semi-chronic segments contribute 70% of total revenue with 38 brands exceeding INR 10 crore sales.Company remains net cash surplus and is one of only three Indian firms to in-license from Ferring Pharmaceuticals.
👀 கவனிக்க வேண்டியவை
The stock is a strong growth play in the domestic branded formulations space given the 20% PAT growth guidance. Investors should monitor the ramp-up of the newly commissioned Gujarat facility and the successful integration of the Bayer Zydus portfolio.
CORONA Remedies Outpaces Market with 16.8% Revenue CAGR and 71% Chronic Portfolio Focus
CORONA Remedies, which listed in December 2025, has demonstrated a strong 16.8% revenue CAGR, outperforming the Indian Pharmaceutical Market (IPM) growth by 1.82x. The company has successfully shifted its focus toward chronic therapies, which now account for 71.1% of its portfolio compared to 69.1% in FY23. With a robust manufacturing base and recent capacity expansion of 400 million tablets at its Gujarat facility, the company is scaling its 27 'Engine' brands. Strategic acquisitions from Bayer Zydus and GSK continue to drive market share in high-growth segments like Women's Healthcare and Pain Management.
முக்கிய அம்சங்கள்
Achieved a 16.8% Revenue CAGR, growing at 1.82x the rate of the Indian Pharmaceutical Market (IPM).Chronic therapy segment contribution rose to 71.1% of total revenue, reflecting a high-margin product mix.Commenced additional production of 400 million tablets at the EU-GMP certified Gujarat facility on December 22, 2025.Holds significant market positions including #5 in Pain Management and #6 in Women’s Healthcare in India.Portfolio includes 71 brands with 27 'Engine' brands, supported by a pan-India distribution network.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to scale its newly added manufacturing capacity and the integration of brands acquired from Bayer Zydus. The high concentration in chronic therapies and domestic market focus provides a defensive yet high-growth profile.
CORONA Remedies Q2 FY26 PAT Jumps 21.8% YoY to ₹52.32 Cr; Revenue Up 15.1%
CORONA Remedies reported a strong financial performance for Q2 FY26, with revenue growing 15.1% YoY to ₹361.13 Cr and PAT increasing 21.8% to ₹52.32 Cr. For the first half of the year (H1 FY26), the company saw a significant 35.1% jump in PAT, reaching ₹98.52 Cr. The company maintained healthy operational efficiency with an EBITDA margin of 21.7% and reported an impressive annualised RoCE of 49.7%. Management highlighted that their growth continues to outperform the Indian Pharmaceutical Market (IPM) through a focus on specialist prescriptions.
முக்கிய அம்சங்கள்
Q2 FY26 Revenue from operations grew 15.1% YoY to ₹361.13 Cr.H1 FY26 Profit After Tax (PAT) surged 35.1% YoY to ₹98.52 Cr.Strong return ratios with annualised RoE at 31.1% and RoCE at 49.7%.Efficient working capital management with Net Working Capital cycle at 23 days.Healthy cash flow generation with OCF to EBITDA ratio at 76.5%.
👀 கவனிக்க வேண்டியவை
The company's high return ratios and efficient working capital cycle make it a strong performer in the mid-cap pharma space. Investors should monitor the earnings call on January 5, 2026, for further outlook on market share gains in core therapeutic segments.
CORONA Remedies Boosts Capacity by 400 Million Units at Bhayla Facility
CORONA Remedies has commenced additional commercial production of tablets and capsules at its Bhayla manufacturing facility as of December 22, 2025. The expansion adds 400 million units to the installed capacity and 240 million units to the available capacity. This move follows a high capacity utilization of 93.58% as of March 2025, where the company produced 561.49 million units against an available capacity of 600 million. Significantly, the entire expansion has been funded through internal accruals, reflecting a strong balance sheet.
முக்கிய அம்சங்கள்
Additional commercial production of tablets/capsules commenced on December 22, 2025.Installed capacity increased by 400 million units; available capacity increased by 240 million units.Previous capacity utilization was at a high 93.58%, indicating a clear need for expansion.The expansion project was funded entirely through internal accruals without external debt.Strategic move aimed at meeting upcoming market demand and improving supply chain agility.
👀 கவனிக்க வேண்டியவை
Investors should view this expansion positively as it addresses capacity constraints and is funded without debt. Monitor the ramp-up of this new capacity and its impact on top-line growth in the next few quarters.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
